Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Sponsor: Kyowa Kirin, Inc.
Listed as NCT04745234, this PHASE2 trial focuses on Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed and remains ongoing. Sponsored by Kyowa Kirin, Inc., it has been updated 10 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — May 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .